We Think ArriVent BioPharma (NASDAQ:AVBP) Can Afford To Drive Business Growth

Simply Wall StSep 24 08:40 ET

LifeSci Capital Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Maintains Target Price $38

Moomoo NewsSep 23 16:31 ET · Ratings

Citi Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Raises Target Price to $36

Moomoo NewsSep 11 06:31 ET · Ratings

ArriVent BioPharma Is Maintained at Buy by Goldman Sachs

Dow JonesSep 10 10:06 ET · Ratings

Oppenheimer Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Raises Target Price to $39

Moomoo NewsSep 10 07:31 ET · Ratings

Analysts Offer Insights on NA Companies: ArriVent BioPharma, Inc. (AVBP) and Rubrik, Inc. Class A (RBRK)

TipRanksSep 10 07:30 ET · Ratings